Connect with us

Health

As the U.S. Exits Foreign Aid, Who Will Fill the Gap?

Published

on

As the U.S. Exits Foreign Aid, Who Will Fill the Gap?

As the reality sets in that the United States is drastically diminishing its foreign assistance to developing countries, an urgent conversation is starting among governments, philanthropists, and global health and development organizations.

It is centered on one crucial question: Who will fill this gap?

Last year, the United States contributed about $12 billion to global health, money that has funded treatment of H.I.V. and prevention of new infections; children’s vaccines against polio, measles and pneumonia; clean water for refugees; and tests and medications for malaria.

The next largest funder is the Gates Foundation, which disburses a fraction of that amount: its global health division had a budget of $1.86 billion in 2023.

“The gap that has been filled by the U.S. cannot be easily matched by anybody,” said Dr. Ntobeko Ntusi, the chief executive of the South African Medical Research Council.

Advertisement

U.S. assistance has been channeled through the United States Agency for International Development, or U.S.A.I.D., which the new Trump administration has largely dismantled, and other government agencies, including the National Institutes of Health, which is also facing substantial cuts in health research grants.

Many people are suggesting that other countries, particularly China, could move into some of the areas vacated by the United States, Dr. Ntusi said. Others are making urgent appeals to big philanthropies including the Gates Foundation and Open Philanthropy.

This conversation is most consequential in Africa. About 85 percent of U.S. spending on global health went to programs in or for African countries.

For countries such as Somalia, where U.S. aid made up 25 percent of the government’s whole budget, or Tanzania, where the U.S. funded a majority of public health care, the loss is catastrophic. And for the major global health agencies, the situation is similarly critical.

President Trump has already pulled the U.S. out of the World Health Organization, which is now trying to make an initial budget cut of $500 million for 2026-27 to cope with the withdrawal of American funds.

Advertisement

Most of our neighbors on the continent, they’ve been completely reliant on the U.S. to procure most of the lifesaving medications for endemic infections,” Dr. Ntusi said. “And I don’t see most of the governments overnight being able to have the resources to cope. And so I think there’s going to be devastating consequences on lives lost from Africans who will die of preventable infections”

The U.S. is the largest donor to Gavi, an organization that supplies essential vaccines to the world’s poorest countries, and to the Global Fund to Fight AIDS, Tuberculosis and Malaria. The U.S. contribution is required by Congress. Asked about the commitment to these and other multilateral agencies including the Pandemic Fund, a State Department spokesperson said that the programs were being reviewed to see if they aligned with the national interest, and that funding would continue only for those that met this condition.

There is no indication that additional funding will come from the other G7 countries, the European Union or other high-income nations. Britain, Germany, France, the Netherlands and Scandinavian countries have all reduced their foreign aid. Some new donor countries have come forward to support the W.H.O., including Saudi Arabia and South Korea, but their spending is dwarfed by the amount the U.S. once gave.

Of nongovernmental players, the World Bank is best placed to provide long-term support for health spending. The bank has said little so far. It could offer countries hit hard by the U.S. cutoff innovative financing such as debt-for-health-care swaps to give nations struggling under heavy debt burdens some fiscal freedom to make up lost health care funding. However, the U.S. is the largest shareholder of the bank, and the Trump administration would have influence over any such investment.

Much of the public discussion about filling the vacuum left by the U.S. has focused on China, which has built a significant presence by financing infrastructure projects in African countries, particularly those with extensive mineral reserves or strategic ports.

Advertisement

“There is good reason for them to do so,” said Ja Ian Chong, an associate professor of political science at the National University of Singapore. China regards foreign aid as a soft-power tool in its superpower rivalry with the United States, much as the United States did when setting up U.S.A.I.D. during the height of the Cold War with the Soviet Union. China seeks to use aid to garner more support from developing countries in the United Nations.

While Chinese aid has largely come in loans to build infrastructure, it includes support for more varied projects. China’s answer to Western development aid, a program unveiled in 2021 called the Global Development Initiative, includes $2 billion for upgrading livestock production in Ethiopia, fighting malaria in Gambia and planting trees in Mongolia, among other projects.

Mr. Chong said China’s ability to fill the opening left by U.S.A.I.D. could be constrained by its own financial limitations. China’s economy has stagnated because of a property crisis and rising government debt, and the country has already scaled back on big infrastructure loans.

To date, China has shown little interest in supporting global health programs, or in providing grants on a scale anywhere near U.S.A.I.D. levels. AidData, a university research lab at William & Mary in Virginia, estimates that Beijing provides about $6.8 billion a year in grants and low-cost loans.

Philanthropies that were already working in global health have been deluged with panicked calls from organizations with frozen funds.

Advertisement

I have talked to some foundations who have all said we’re being inundated with people saying, ‘Help us, help us, help us,’ and I think they’re trying to patch little holes,” said Sheila Davis, the chief executive of the nonprofit Partners in Health, which works with local governments to bring health care to communities in developing countries. But if a patchwork bailout can cover just 20 percent of what the U.S. was paying for, what should a new donor save? she asked. “Do you choose to save one program fully and then let others go? Or what is the best strategy?”

Chief among the foundations fielding pleas for help is the Gates Foundation, which has been warning its grant recipients that it cannot make up the gap. In addition to funding global health programs, the foundation also supports health research and is a major contributor to Gavi.

“There is no foundation — or group of foundations — that can provide the funding, work force capacity, expertise, or leadership that the United States has historically provided to combat and control deadly diseases and address hunger and poverty around the world,” the foundation’s North America director, Rob Nabors, said by email.

Multiple recipients of Gates Foundation funding, who declined to speak on the record because they were describing confidential conversations, said they had been told by foundation staff members that it would continue to fund research and programs in the areas it already worked, but wouldn’t expand significantly, and that while some grants might be restructured to try to compensate for part of the lost U.S. funding, the foundation’s work would continue to be “catalytic” rather than support large-scale programming like U.S.A.I.D. did.

John-Arne Røttingen, the chief executive of the Wellcome Trust, which is among the largest donors to global health research, said in an email that the foundation was “exploring what options might exist” in the new landscape. But, he said, its help would be “a drop in the ocean compared to what governments across the world need to provide.”

Advertisement

A couple of small organizations, such as Founders Pledge, have started “bridge funds,” ranging from about $20 million to $200 million, to try to help plug immediate gaps.

But the philanthropic sector has largely been silent about the momentous change in the landscape. Major players that have already put hundreds of millions of dollars into health care in Africa, such as the Susan T. Buffett Foundation, did not respond to questions about their plans. The Delta Foundation (co-founded by the Zimbabwean telecom billionaire Strive Masiyiwa) declined to discuss the issue.

Two executives at smaller private foundations said there was a reluctance to say anything publicly because of fear of retribution from the Trump administration, including a potential loss of charitable status.

African governments are under tremendous pressure from frustrated citizens to assume responsibility for the health spending that was coming from the U.S. The issue led the agenda at a meeting of the continent’s health ministers at an African Union summit last week.

In the 24 years since the Union adopted what’s called the Abuja Declaration, committing its 42 members to spending 15 percent of their budgets on health, only a couple of states have ever hit that target, and for a year or two at most. Average health spending by African countries is less than half that amount.

Advertisement

In Nigeria, the president convened an emergency cabinet committee to make a plan for the budget shortfall, and Parliament allotted an extra $200 million to the national budget last week. But that extraordinary measure illustrates the scale of what’s been lost: it’s less than half of the $512 million that the U.S. gave Nigeria for health care in 2023.

Nigeria’s health minister, Dr. Muhammad Pate, said that nearly 28,000 health care workers in the country had been paid in whole or part by U.S.A.I.D., which also covered three-quarters of the bill for drugs and test kits for the 1.3 million Nigerians who live with H.I.V.

Nigeria will quickly need to find new ways of operating, he said, including boosting manufacturing of some of those items domestically. “It may not be as fancy, but at least it will serve,” Dr. Pate said.

He also predicted that the end of U.S. aid would accelerate what he called a “realignment” in Africa. “The world has shifted in the last 20 years,” he said. “So we have other actors: We have China, India, Brazil, Mexico and others.”

Deisy Ventura, a professor of global health ethics at the University of São Paulo, said the change could open opportunities for other countries to exert newfound influence.

Advertisement

“The retreat of the United States may open space for new leaders now,” she said. “It’s important for us in the global south to imagine an international coordination of emergency preparedness and response without the United States.”

Berry Wang contributed reporting from Hong Kong.

Health

This Vegan Eating Trick Helps People Lose 30 to 85 Lbs and Get Healthier

Published

on

This Vegan Eating Trick Helps People Lose 30 to 85 Lbs and Get Healthier


Advertisement





A Vegan Diet Without Oil Helps Women Reverse Diabetes and Lose Weight




















Advertisement





Advertisement


Use left and right arrow keys to navigate between menu items.


Use escape to exit the menu.

Advertisement

Continue Reading

Health

Diabetes drug could slash risk of fatal heart condition in one group, scientists reveal

Published

on

Diabetes drug could slash risk of fatal heart condition in one group, scientists reveal

NEWYou can now listen to Fox News articles!

A diabetes drug could help lower the risk of heart failure in certain patients.

A new study published in Nature Medicine analyzed how SGLT2 inhibitor dapagliflozin, a medication used to treat type 2 diabetes, could help prevent heart failure in people with rare genetic variants linked to cardiomyopathy (a progressive disease of the heart muscle).

Using data from the DECLARE-TIMI 58 trial, researchers from Harvard Medical School, Mass General Brigham and MIT looked at more than 12,000 adults who had type 2 diabetes and increased cardiovascular risk.

VITAMIN SUPPLEMENT MAY DELAY DIABETES IN SELECT GROUPS, RESEARCHERS SAY

Advertisement

About 121 participants carried inherited gene variants that could raise their chances of developing cardiomyopathy.

After a median 4.2-year follow-up, dapagliflozin was found to lower hospitalization for heart failure more in individuals with the variants than in those without.

Dapagliflozin was found to lower hospitalization for heart failure in individuals with the variants for cardiomyopathy more than those without them. (iStock)

While dapagliflozin lowered heart failure hospitalization in both groups, the reduction was about eight times stronger in carriers of the genetic variant.

Among the 82% of carriers without a prior history of heart failure, 12.8% developed heart failure in the placebo group, while no heart-failure events were observed among carriers receiving dapagliflozin.

Advertisement

DIABETES STUDY REVEALS DIAGNOSIS GAP AFFECTING MILLIONS OF PEOPLE

Co-lead study author Shinwan Kany, MD, a visiting scientist at the Cardiovascular Research Center with Mass General Brigham Heart and Vascular Institute and the Broad Institute, commented on how these findings could shape preventive care.

“Historically, identifying a genetic variant for cardiomyopathy mostly meant telling a patient they were at high risk and not having a specific preventive therapy to offer,” he said in a press release. “These data show we do have tools to lower risk in these individuals.”

In the placebo group, carriers had about eight times higher risk of hospitalization compared to non-carriers. (iStock)

As this was an analysis of a larger randomized trial, the results require further confirmation, according to experts. The narrow sample size of carriers also poses a limitation.

Advertisement

DIABETES, HEART DISEASE CASES SKYROCKET — AND SCIENTISTS PINPOINT ONE KEY REASON

“These findings are very encouraging because they suggest we may be entering an era where heart failure prevention becomes more precise and more genetically informed,” Andrew Freeman, MD, a cardiologist at National Jewish Health, told Fox News Digital.

Freeman, who was not involved in the study, called the research “important and provocative.”

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

Participants with no history of heart failure who took dapagliflozin were less likely to develop the condition, a finding that “raises the possibility that SGLT2 inhibitors may be especially useful as preventive therapy in genetically high-risk individuals,” the doctor said.

Advertisement

Dapagliflozin is a prescription medication used to manage type 2 diabetes, heart failure and chronic kidney disease. (iStock)

“This should be viewed as an exciting hypothesis-generating finding, not yet a practice-changing mandate for all patients with these genetic variants,” Freeman cautioned.

SGLT2 inhibitors are already “foundational” cardiovascular and kidney-protective medications, the doctor noted.

CLICK HERE FOR MORE HEALTH STORIES

“They reduce heart failure hospitalization across a broad range of patients, including those with diabetes, chronic kidney disease and established heart failure,” he said. “What this study adds is the possibility that genetic information may help identify a subgroup of people who derive especially large benefit from early treatment.”

Advertisement

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

Genetic testing for cardiomyopathy is often used for diagnosis, family screening and risk stratification, Freeman said.

If future clinical trials confirm the findings, cardiologists could eventually use genetic screening to identify high-risk patients, monitor them more closely, and begin treatments such as SGLT2 inhibitors before heart failure symptoms appear, according to the cardiologist.

Genetic testing for cardiomyopathy is often used for diagnosis, family screening and risk stratification. (iStock)

Heart failure does not always begin when symptoms appear, Freeman noted. In some patients, risk may be present years earlier due to inherited genetics.

Advertisement

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

Preventive cardiology could identify high-risk patients earlier, before they develop symptoms such as shortness of breath, fluid retention or the need for hospitalization.

The decision to medicate should always be discussed with a clinician, Freeman advised, especially for those with a personal or family history of cardiovascular events.

Continue Reading

Health

Woman with advanced Alzheimer’s regained speech and memories after taking magic mushrooms

Published

on

Woman with advanced Alzheimer’s regained speech and memories after taking magic mushrooms

NEWYou can now listen to Fox News articles!

A woman with advanced Alzheimer’s disease saw significant improvements in brain function after taking psilocybin-containing mushrooms.

That’s according to a case report recently published in Frontiers in Neuroscience, which focused on an elderly woman who had been living with Alzheimer’s disease for about 10 years. 

The Japanese American woman, whose name was not shared, had experienced severe functional decline for roughly five years. The Brazilian study authors described her as having advanced dementia, with very limited speech or communication, severe cognitive impairment, urinary incontinence and reduced mobility.

THE KEY TO LIVING LONGER COULD BE TIED TO A SURPRISING SUBSTANCE, STUDY SUGGESTS

Advertisement

She also depended on caregivers for assistance with daily living activities.

The woman received two sessions of psilocybin-containing mushrooms. The first was a 5-gram oral dose, followed by a 3-gram oral dose a month later.

A woman with advanced Alzheimer’s disease saw significant improvements in brain function after taking psilocybin-containing mushrooms, according to a published case report. (iStock)

After the first dose, she experienced profuse sweating and hyperthermia, followed by a prolonged sleep-like state.

Approximately 19 hours later, the patient “spontaneously initiated autobiographical conversation lasting several hours,” the researchers wrote.

Advertisement

Over the following days and weeks, the woman experienced restored urinary continence, was able to walk independently and dress herself, and engaged in spontaneous conversation. She was also able to retrieve contextual memories, showed the ability to express emotions and maintained eye contact — smiling with others.

TWO ALZHEIMER’S DRUGS HELP PATIENTS LIVE INDEPENDENTLY AT HOME FOR LONGER PERIODS

After the second session, the authors reported that the woman had even greater speech capabilities, more facial expressions and humor, increased walking agility and continued continence.

Beyond the heavy sweating, hyperthermia and sleep-like state, the patient did not experience severe or persistent adverse effects, the researchers noted.

After the second session, the authors reported that the woman had even greater speech capabilities, more facial expressions and humor, increased walking agility and continued continence. (James MacDonald/Bloomberg via Getty Images)

Advertisement

Although the reported benefits lasted for at least one month, the paper does not provide longer-term follow-up.

The authors said the findings should be interpreted with caution, as they are based on a single patient.

EXPERTS REVEAL HIDDEN LINK BETWEEN POOR SLEEP AND ALZHEIMER’S DISEASE RISK

The case also included no control group, standardized cognitive assessments, brain imaging biomarkers, electrophysiological monitoring or sleep studies, they noted.

The patient’s Alzheimer’s diagnosis was not confirmed with modern biomarkers, and other neurodegenerative conditions could not be completely ruled out, the study stated.

Advertisement

As the patient may have experienced natural fluctuations in her medical condition, the study could not establish that psilocybin directly caused the woman’s improvements.

After the second session, the authors reported that the woman had increased walking agility. (iStock)

While the study suggests that psilocybin-containing mushrooms could temporarily reactivate brain function in people with late-stage dementia, the authors noted that controlled clinical trials, cognitive assessments, imaging scans and other tests are needed to confirm the findings.

CLICK HERE FOR MORE HEALTH STORIES

“Much more research is needed in larger, more representative study populations before any conclusions can be drawn about psilocybin’s safety and effectiveness in people living with Alzheimer’s or any other disease that causes dementia,” Courtney Kloske, Ph.D., director of scientific engagement at the Alzheimer’s Association in Chicago, told Fox News Digital.

Advertisement

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

Kloske, who was not involved in the study, emphasized that people living with Alzheimer’s and their caregivers should talk with their doctor about all medications, vitamins, supplements and other substances they are taking.

“This helps healthcare providers understand how these products may interact with approved Alzheimer’s medications and other therapies to determine whether they could lead to unwanted side effects,” she advised.

“It might have some value in a carefully controlled setting.”

Dr. Marc Siegel, Fox News senior medical analyst, said he is “dubious” of the significance of the study because the effect was described as temporary and was limited to one case.

Advertisement

“Also, there is a built-in danger of giving a hallucinogen to someone with this degree of mental impairment, because the behavioral effects are largely unpredictable and can be harmful,” Siegel, who also was not involved in the study, told Fox News Digital.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

“Having said that, I am not surprised to see that psilocybin could temporarily overcome or alter the gummed-up [brain] circuitry (with plaques) of advanced Alzheimer’s disease – so it might have some value in a carefully controlled setting.”

A medical expert said he is “dubious” of the significance of the study because the effect was described as temporary and was limited to one case. (Ethan Barton/Fox News Digital)

The findings come as several states have expanded legal access to psilocybin. (The substance remains federally illegal in the U.S. as a Schedule I substance.)

Advertisement

Oregon began licensing psilocybin service centers in 2023, Colorado’s regulated natural medicine program became operational in 2025, and New Mexico enacted a Medical Psilocybin Act in 2025, according to state officials.

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

Still, there are currently no FDA-approved psilocybin treatments for Alzheimer’s disease or dementia, and legal access remains limited to certain state-regulated programs or approved research settings.

Fox News Digital reached out to the researchers for comment.

Advertisement
Continue Reading
Advertisement

Trending